综合监管制度政策解读和评价

2018-08-04 薛澜 沈群红 国家卫健委

《关于改革完善医疗卫生行业综合监管制度的指导意见》(以下简称《指导意见》)正式颁布,这是我国健康领域治理现代化建设的一个重要进步,意味着我国医疗卫生领域的全行业监管能力建设进入到法治化、制度化、专业化的新阶段,标志着中国医疗卫生领域新型综合监管制度体系基本形成。《指导意见》旨在建立和完善医疗卫生行业的综合监管制度, 从强化政府责任、落实医疗卫生机构主体责任、发挥行业组织自律作用、加强社会监督

《关于改革完善医疗卫生行业综合监管制度的指导意见》(以下简称《指导意见》)正式颁布,这是我国健康领域治理现代化建设的一个重要进步,意味着我国医疗卫生领域的全行业监管能力建设进入到法治化、制度化、专业化的新阶段,标志着中国医疗卫生领域新型综合监管制度体系基本形成。《指导意见》旨在建立和完善医疗卫生行业的综合监管制度, 从强化政府责任、落实医疗卫生机构主体责任、发挥行业组织自律作用、加强社会监督等方面健全机构自治、行业自律、政府监管、社会监督相结合的多元化综合监管体系,并从要素准入、服务质量和安全监管、机构运行监管和公共卫生服务监管等维度来实现全过程的监管。具体来看,《指导意见》有如下特点:

一、旗帜鲜明地把全面保障人民群众的健康权益作为综合监管制度的出发点

公共政策评价的重要内容之一是其价值理念。看一项社会政策是否有利于公共价值的实现和提高,就是要从其出发点、基本原则以及最终的政策效果等维度来衡量。在我国目前的发展阶段和基本国情下,尤其需要分析一项政策的出发点是什么,其与人民群众的根本利益之间是什么关系。医疗卫生行业监管制度是社会性监管体系中的重要组成部分,市场失灵程度高,涉及面广,监管难度大。随着人民群众对美好生活的要求越来越高,医疗卫生领域的安全、质量和有效性,越来越成为广大人民群众关注的重点和热点,成为广大民众健康权益维护和发展的重大关切。

正是在“健康优先发展”的新时代背景下,医疗卫生行业综合监管制度以全面保障人民群众的健康权益,维护广大人民群众的长远的根本利益作为出发点,通过政策法律制订、规范制订、标准和指南制订实施、质量和安全领域的监督等监管行为推进医疗卫生行业综合监管体系的建立,充分体现了健康领域治理所必须遵从的人民性原则。这次颁布的《指导意见》,无论是从监管目标设定、监管原则、监管事项和监管内容等都紧紧围绕医疗卫生领域涉及广大公众各项利益的方方面面,依法构建科学严密规范的监管制度,最大限度地保障人民群众的健康权益,体现了一切为了人民健康的以人为本的治理理念。

从维护和促进人民群众健康权益的角度出发,《指导意见》敢于直面医疗卫生领域出现的新情况、新问题和新挑战,以主动积极,勇于担当的精神,以社会风险系统治理的先进理念为指导,以社会监管和社会治理的系统方法为支持,以建立全行业全过程的综合监管为重点,回应基本健康需要和多元健康需要,建立适合发展新形势的监管体系,是负责任的服务型政府的应有举措,充分体现了健康中国国家发展战略和小康社会建设的根本要求。

二、清晰地界定了医疗卫生行业中政府与服务机构的关系,为健康领域建立依法共建共治共享的治理机制打下基础

《指导意见》通过医疗卫生机构综合监管制度的完善,为医疗卫生行业中各类主体相应的责权利界定提供了有效的制度基础,为良好的治理体系提供了重要的制度保障。这是中国健康领域监管体系建设和治理能力建设中法治化的必要体现。有了这个制度安排和相关的法律条款,共建共治共享的治理机制才能将政府监管、机构自治、行业自律、社会监管和公众参与等治理元素有机地结合起来,成为医疗卫生领域中多元治理的重要组成部分。在这样的治理体系中,围绕着保障公众健康权益这一共同目标,各组成部分依法清晰界定各自法律地位和相关的权力义务关系,以构建各类主体通过有效共治实现共建共享的新型治理模式。

尤其值得注意的是,该全行业综合监管制度清晰地界定了政府与医疗卫生服务机构的关系,特别是政府与公立医疗卫生机构之间的关系。政府作为全行业监管的主导力量和主要监管责任主体,与公立医疗卫生机构更为本质的是监管和被监管的关系,正如《指导意见》所指出的“所有医疗卫生机构不论所有制、投资主体、隶属关系和经营性质,均由所在地政府卫生健康行政部门(含中医药管理部门)实现统一监管”。这一关系的确立,有利于明晰各级政府与各类各级医疗卫生机构的关系。

三、积极推进全行业、全过程、全要素、多主体的监管体系和监管制度的建立

当前,全方位全过程的全面健康服务模式不断推进,医疗卫生领域中各类新技术、新主体、新业态快速发展,医疗卫生领域的开放性和复杂性不断提高,日益复杂多元的各类主体不断涌入医疗卫生行业,给新形势下有效监管医疗卫生行业提出了重大挑战。任何有效的监管体系必须覆盖医疗卫生服务领域中的各类行业形态、医疗卫生服务过程各个环节、服务过程中的各类要素,以及各类所有制、各类投资主体、各类经营性质服务的提供主体。这一监管体系要求的是不同领域和不同议题上政策间的高度融合、是各相关政府部门和机构间的高度协同,以及各类监管方式和监管工具的综合使用。任何单一部门、单一方式和单一手段基本上无能为力,无法与被监管事务和对象的高度复杂多样和高度动态变化的实际相匹配。此次《指导意见》的出台,主动地采用全行业全过程的综合监管思路,有利于整合各类监管主体的资源和能力,在更为综合集成的平台上实施信息集成、资源整合、权力适当集中,从而以提高监管的权威性和有效性。随着此次综合监管制度的出台,以往的政出多门与问责真空同在、重复无序检查与监管盲点并存、权力过度分散与部门利益丛生长期共存等问题将可以得到有效解决。

四、实现了从传统的行政性管控到被动孤立监控再到主动综合协同监管的转变

中国医疗卫生领域的监管制度也正在发生深刻的变化。传统的行政性管控从根本上来说是基于封闭的、将医疗卫生服务机构视为行政系统内下属单位的旧的治理模式,采用内部一体化的行政管控来完成对相关服务的质量控制。而后建立的第二代监管模式虽然跳出了传统的行政体系,但仍然采取就事论事,强调外部检查监督为主的监管模式,这种模式在中国的社会性监管领域中比比皆是。但从中国社会性监管领域风险事件频发、事件发生后的运动式的高压整顿、导致监管体系疲于应付的现实来看,此类治理模式的局限性也是比较明显的。而顺应新时代要求,跟随国际监管大势,建立积极主动、综合协同的监管体系势在必行。

新一代的监管模式强调对相关风险的前瞻治理。在本次颁发的《指导意见》中,在强调医药卫生健康机构是最为主要的责任主体的同时,还特别强调了通过机构自治和行业自律(如机构内或行业内的质量管理体系和风险管理体系)来提高风险识别和管理水平,主动降低和消解影响民众健康权益的不良事件,建立风险预警和评估机制,形成统一的医疗卫生服务质量、安全和费用风险监测评估网络。这些举措都充分体现了积极主动的风险治理意识,是社会风险前瞻治理思想在医疗卫生领域监管制度建设中的具体应用。

新一代监管模式突出多部门多领域合作的协同治理。为了适应医疗卫生领域的开放性、复杂性、和动态性,还需要强调多部门多领域合作的协同治理的思想,需要相关政策法律制度的整合、需要政府各部门间的分工协作各尽其责,也需要政府、专业机构、社会组织和社会舆论间的协同。其中,政府部门间的协同是重点和难点。例如,虽然医疗卫生领域的监管工作主要涉及社会性监管,但在涉及到与药品、器械和耗材等医疗卫生机构投入品有关领域的准入和价格等方面也与经济性监管密切相关,既需要医疗卫生的行业管理部门肩负准入、质量安全监管等方面的职责,也需要医疗保险部门履行保险定点机构/团队,费用控制和质量监督等方面的职责。同时,对不法个体和服务机构的监督、约束、和处罚还涉及到工商、金融和公安等部门的相互支持及紧密配合。相关部门间的有效协同将有利促进一个公平高效监管体系的建立,协同治理的思想是该体系有效推进和健康领域治理体系和治理能力提升的重要理论指导。

新一代监管模式采用督察机制来促进中央和地方相关部门各尽其责、分工协作。医疗卫生全行业监管最为重要的监管主体是属地政府,但由于中央政府与地方政府之间的信息不对称所导致的上有政策下有对策的现象也是普遍存在的。为了提高综合监管制度的权威性、有效性和公正性,需要通过行政督察等方式来评价政府分管领导的责任落实情况、省(区、市)有关部门综合监管职责的履行情况。中央和地方的督察体系和督察机制的建立是该项制度的又一特色。目前,我国环保监管、安全生产监管等领域中都建立了综合监管基础上的行政督察机制,取得了较好的治理成效。在医疗卫生全行业领域建立全过程的督察机制,有利于克服监管力量分散、监管信息共享不足、监管职能难以有效衔接和监管结果未能联合应用等问题,也有利于提高综合监管工作自身的规范化程度和专业化水平,提高其权威化程度和公正性程度。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=340927, encodeId=82b534092eff, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 26 19:49:03 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338746, encodeId=d444338e46e3, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Aug 15 11:28:23 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260366, encodeId=9acb126036650, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371552, encodeId=a1cc13e155273, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444413, encodeId=941a1444413a3, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336450, encodeId=535b336450fa, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Aug 04 23:25:52 CST 2018, time=2018-08-04, status=1, ipAttribution=)]
    2018-08-26 大爰

    学习了谢谢分享!!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=340927, encodeId=82b534092eff, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 26 19:49:03 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338746, encodeId=d444338e46e3, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Aug 15 11:28:23 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260366, encodeId=9acb126036650, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371552, encodeId=a1cc13e155273, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444413, encodeId=941a1444413a3, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336450, encodeId=535b336450fa, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Aug 04 23:25:52 CST 2018, time=2018-08-04, status=1, ipAttribution=)]
    2018-08-15 大爰

    学习并分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=340927, encodeId=82b534092eff, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 26 19:49:03 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338746, encodeId=d444338e46e3, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Aug 15 11:28:23 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260366, encodeId=9acb126036650, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371552, encodeId=a1cc13e155273, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444413, encodeId=941a1444413a3, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336450, encodeId=535b336450fa, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Aug 04 23:25:52 CST 2018, time=2018-08-04, status=1, ipAttribution=)]
    2018-08-06 bioon3
  4. [GetPortalCommentsPageByObjectIdResponse(id=340927, encodeId=82b534092eff, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 26 19:49:03 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338746, encodeId=d444338e46e3, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Aug 15 11:28:23 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260366, encodeId=9acb126036650, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371552, encodeId=a1cc13e155273, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444413, encodeId=941a1444413a3, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336450, encodeId=535b336450fa, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Aug 04 23:25:52 CST 2018, time=2018-08-04, status=1, ipAttribution=)]
    2018-08-06 wwzzly
  5. [GetPortalCommentsPageByObjectIdResponse(id=340927, encodeId=82b534092eff, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 26 19:49:03 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338746, encodeId=d444338e46e3, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Aug 15 11:28:23 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260366, encodeId=9acb126036650, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371552, encodeId=a1cc13e155273, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444413, encodeId=941a1444413a3, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336450, encodeId=535b336450fa, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Aug 04 23:25:52 CST 2018, time=2018-08-04, status=1, ipAttribution=)]
    2018-08-06 huagfeg
  6. [GetPortalCommentsPageByObjectIdResponse(id=340927, encodeId=82b534092eff, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 26 19:49:03 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338746, encodeId=d444338e46e3, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Aug 15 11:28:23 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260366, encodeId=9acb126036650, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371552, encodeId=a1cc13e155273, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444413, encodeId=941a1444413a3, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Mon Aug 06 13:28:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336450, encodeId=535b336450fa, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sat Aug 04 23:25:52 CST 2018, time=2018-08-04, status=1, ipAttribution=)]
    2018-08-04 1e1b8538m79(暂无匿称)

    不错的文章值得拥有哦

    0

相关资讯

北京病案首页质量管理新规 统一标准全程监管

近日,北京市卫生和计划生育委员会、北京市人力资源和社会保障局共同发布了《关于加强住院病案首页质量管理工作的通知》。具体通知如下:北京市卫生和计划生育委员会 北京市人力资源和社会保障局 关于加强住院病案首页质量管理工作的通知各区卫生计生委、人力社保局、各有关医疗机构:为做好医药分开综合改革后续工作,加强医疗机构住院病案首页质量管理,提升首页数据质量,为医保支付方式改革和医疗服务能力评价提供支持,根

警惕!又有畅销药被查封了...

源头把控,这次又有39批次药品被通告了。包括感冒解毒颗粒、小儿氨酚黄那敏颗粒等畅销药。

《中医药监督工作指南(测试版)》印发

为进一步贯彻落实党的十九大、全国卫生与健康大会精神,全面推进依法治国,加强事中事后监管,着力推进中医药监督执法工作开展,为各地区开展中医药监督工作提供指导依据,制定本方案:

医疗卫生国家随机抽检来了,重点查这些!

医疗卫生国家随机抽查来了!对比去年大抽检,今年有了新变化,大家一定要注意!

104药企要被查!

1月23日下午,山西省食药监局连续发布两条重磅通知,部署2018年度药品GMP跟踪检查和药品不良反应监测工作。

护理安全无小事,谨防烟民酿火灾!

护理工作本就已千头万绪,要管患者的吃喝拉撒,用药打针,翻身拍背,抢救处理,这些就已经让人忙的脚不沾地了,可还有一些患者让护士不省心,那就是——烟民。